Rohrabacher substitute patent amendment to HR 400 rejected on 178-227 vote.
REP. ROHRABACHER SUBSTITUTE PATENT AMENDMENT DEFEATED BY 178-227 VOTE during House consideration of Rep. Howard Coble's (R-N.C.) Patent & Trademark Office reform package (HR 400) on April 17. The House plans to continue consideration of HR 400 on April 23. Ten amendments, including the manager's amendment sponsored by Coble, are pending, although more could be introduced under the bill's open rule.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth